All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2026-05-15.
From the record
Oramed Pharmaceuticals Inc.'s filings since 2017 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-05-15) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+13% a year over 9 filed years; profitable in 2 of 10.
From the record
Oramed Pharmaceuticals Inc.'s 9 filed years say what it did: revenue went from $641 thousand in fiscal 2016 to $2 million in fiscal 2025, up 13% a year; it rose in 5 of 8 years; the deepest fall was 51% from fiscal 2020 to fiscal 2023; net income was positive in 2 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 2.8% a year. 14% of cash flow returned. Insiders: 4 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Oramed Pharmaceuticals Inc.'s diluted share count grew about 2.8% a year, and dividends and buybacks returned about 14% of its net income over 3 years (its filed statements). Its officers and directors filed 4 sales (2 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 32%: 32¢ of profit per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Oramed Pharmaceuticals Inc. earned about 32 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 13 cents per dollar of assets, and net share issuance: its share count grew 3.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 48% of 315 in its family; net margin 3202.5%.
From the record
Oramed Pharmaceuticals Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 28% by size; a net margin of 3202.5% ranks in the top 1%; revenue growth of -6.7% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 38% of 315 in its family for leadership; chief executive since 2007.
From the record
Oramed Pharmaceuticals Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kidron, Nadav (President and CEO, as filed), filing under that title since 2007-08-03, 19.3 years (top 3% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 7.2 years (top 27%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (bottom 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 36% of 273 in its family for room to expand.
From the record
Oramed Pharmaceuticals Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $46 million against no long-term debt tagged leaves 19.9% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is -457.7% of revenue (bottom 35%); a gross margin of 0.7% (bottom 5%); research spending of 319.1% of revenue (top 37%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 25% of 306 in its family for growth drivers.
From the record
Oramed Pharmaceuticals Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -6.7% a year over the last three filed years against 13% over all 9, slowing (bottom 26% of its family); the newest year grew 22.2% (top 36%); research spending grew -38.6% a year (bottom 8%); capital spending grew -73.7% a year (bottom 3%) (its annual reports). Oramed Pharmaceuticals Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 9% of 233 in its family for expectations against reality.
From the record
Oramed Pharmaceuticals Inc.'s newest year against its own record: revenue of $2 million in fiscal 2025 came in 101.6% above the $992 thousand its prior three years' pace pointed to (top 14% of its family); net income of $64 million against a prior three-year average of $18 million (top 4%); a net margin of more than its whole revenue against losses larger than its revenue before (top 9%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made